Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Aortic Valve Replacement | Research article

Restricted mean survival time of older adults with severe aortic stenosis referred for transcatheter aortic valve replacement

Authors: Julia Rodighiero, Nicolo Piazza, Giuseppe Martucci, Marco Spaziano, Kevin Lachapelle, Benoit de Varennes, Marie-Claude Ouimet, Jonathan Afilalo

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

Few studies have measured frailty as a potential reason for foregoing transcatheter aortic valve replacement (TAVR) in older adults with severe aortic stenosis (AS). This study sought to determine the impact of frailty and other clinician-cited reasons on restricted mean survival time (RMST).

Methods

An analysis of the McGill Frailty Registry was conducted between 2014 and 2018 at the McGill University Health Center Structural Valve Clinic. Consecutive nonsurgical patients referred for TAVR were included. In those that underwent balloon aortic valvuloplasty or medical management, the primary clinician-cited reason for foregoing TAVR was codified. Vital status was ascertained at 1 year and analysed using RMST and Kaplan-Meier analyses.

Results

The study consisted of 373 patients with a mean age of 82.4 years, of which 233 underwent TAVR and 140 did not. Patients who did not undergo TAVR were more likely to be nonagenarians, with left ventricular dysfunction, chronic kidney disease, dementia, disability, depression, malnutrition, and frailty. The primary clinician-cited reason was: comorbidity in 34%, frailty in 23%, procedural feasibility and risks in 16%, and mild or unrelated symptoms in 27%. Compared to the TAVR group, 1-year RMST was reduced by 2.0 months in the medical management group (95% CI 1.2, 2.7) and by 1.1 months in the valvuloplasty group (95% CI -0.2, 2.5).

Conclusions

Patients with severe AS referred for TAVR may never undergo the procedure on the basis of comorbidity, frailty, procedural issues, and symptoms. The best treatment decision is one that follows from multi-disciplinary assessment encompassing frailty.
Literature
2.
go back to reference Leon MB, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.CrossRef Leon MB, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.CrossRef
3.
go back to reference Galatas C, Afilalo J. Transcatheter aortic valve replacement over age 90: risks vs benefits. Clin Cardiol. 2019;43:1–7. Galatas C, Afilalo J. Transcatheter aortic valve replacement over age 90: risks vs benefits. Clin Cardiol. 2019;43:1–7.
4.
go back to reference Afilalo J, et al. Frailty assessment in older adults undergoing Transcatheter or surgical aortic valve replacement: the frailty-AVR study. J Am Coll Cardiol. 2017;70:689–700.CrossRef Afilalo J, et al. Frailty assessment in older adults undergoing Transcatheter or surgical aortic valve replacement: the frailty-AVR study. J Am Coll Cardiol. 2017;70:689–700.CrossRef
5.
go back to reference Gregson J, et al. Nonproportional hazards for time-to-event outcomes in clinical trials: JACC review topic of the week. J Am Coll Cardiol. 2019;74:2102–12.CrossRef Gregson J, et al. Nonproportional hazards for time-to-event outcomes in clinical trials: JACC review topic of the week. J Am Coll Cardiol. 2019;74:2102–12.CrossRef
6.
go back to reference Kapadia SR, et al. Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replacement. J Thorac Cardiovasc Surg. 2009;137:1430–5.CrossRef Kapadia SR, et al. Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replacement. J Thorac Cardiovasc Surg. 2009;137:1430–5.CrossRef
7.
go back to reference Bach DS, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. Circulation. 2009;2:533–9.PubMed Bach DS, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. Circulation. 2009;2:533–9.PubMed
8.
go back to reference Badran A, Vohra H, Livesey S. Unoperated severe aortic stenosis: decision making in an adult UK-based population. Ann R Coll Surg Engl. 2012;94:416–21.CrossRef Badran A, Vohra H, Livesey S. Unoperated severe aortic stenosis: decision making in an adult UK-based population. Ann R Coll Surg Engl. 2012;94:416–21.CrossRef
9.
go back to reference Everett RJ, Clavel M-A, Pibarot P, Dweck MR. Timing of intervention in aortic stenosis: a review of current and future strategies. Heart. 2018;104:2067–76.CrossRef Everett RJ, Clavel M-A, Pibarot P, Dweck MR. Timing of intervention in aortic stenosis: a review of current and future strategies. Heart. 2018;104:2067–76.CrossRef
10.
go back to reference Kang D, et al. Mortality predictors in patients referred for but not undergoing Transcatheter aortic valve replacement. Am J Cardiol. 2015;116:919–24.CrossRef Kang D, et al. Mortality predictors in patients referred for but not undergoing Transcatheter aortic valve replacement. Am J Cardiol. 2015;116:919–24.CrossRef
11.
go back to reference Szerlip M, et al. Transcatheter aortic valve replacement in patients with end-stage renal disease. J Am Coll Cardiol. 2019;73:2806–15.CrossRef Szerlip M, et al. Transcatheter aortic valve replacement in patients with end-stage renal disease. J Am Coll Cardiol. 2019;73:2806–15.CrossRef
12.
go back to reference Yamamoto M, et al. Prognostic value of chronic kidney disease after Transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;62:869–77.CrossRef Yamamoto M, et al. Prognostic value of chronic kidney disease after Transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;62:869–77.CrossRef
13.
go back to reference Gupta T, et al. Association of Chronic Kidney Disease with in-hospital outcomes of Transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2017;10:2050–60.CrossRef Gupta T, et al. Association of Chronic Kidney Disease with in-hospital outcomes of Transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2017;10:2050–60.CrossRef
14.
go back to reference Takagi H, et al. Meta-analysis of impact of liver disease on mortality after transcatheter aortic valve implantation. J Cardiovasc Med. 2019;20:237–44.CrossRef Takagi H, et al. Meta-analysis of impact of liver disease on mortality after transcatheter aortic valve implantation. J Cardiovasc Med. 2019;20:237–44.CrossRef
15.
go back to reference Hermiller JB, et al. Predicting early and late mortality after Transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:343–52.CrossRef Hermiller JB, et al. Predicting early and late mortality after Transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:343–52.CrossRef
16.
go back to reference Shimura T, et al. Patients refusing Transcatheter aortic valve replacement even once have poorer clinical outcomes. J Am Heart Assoc. 2018;7:e009195.CrossRef Shimura T, et al. Patients refusing Transcatheter aortic valve replacement even once have poorer clinical outcomes. J Am Heart Assoc. 2018;7:e009195.CrossRef
17.
go back to reference Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in Transcatheter aortic valve replacement. Cardiol Clin. 2020;38:75–87.CrossRef Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in Transcatheter aortic valve replacement. Cardiol Clin. 2020;38:75–87.CrossRef
18.
go back to reference Asgar AW, et al. 2019 Canadian cardiovascular society position statement for Transcatheter aortic valve implantation. Can J Cardiol. 2019;35:1437–48.CrossRef Asgar AW, et al. 2019 Canadian cardiovascular society position statement for Transcatheter aortic valve implantation. Can J Cardiol. 2019;35:1437–48.CrossRef
19.
go back to reference Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol. 2017;2:1179–80.CrossRef Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol. 2017;2:1179–80.CrossRef
20.
go back to reference Otto CM, et al. Three-year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. Circulation. 1994;89:642–50.CrossRef Otto CM, et al. Three-year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. Circulation. 1994;89:642–50.CrossRef
21.
go back to reference Lieberman EB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522–8.CrossRef Lieberman EB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522–8.CrossRef
22.
go back to reference Kapadia S, et al. Outcomes of inoperable symptomatic aortic stenosis patients not undergoing aortic valve replacement: insight into the impact of balloon aortic Valvuloplasty from the PARTNER trial (placement of AoRtic TraNscathetER valve trial). J Am Coll Cardiol Intv. 2015;8:324–33.CrossRef Kapadia S, et al. Outcomes of inoperable symptomatic aortic stenosis patients not undergoing aortic valve replacement: insight into the impact of balloon aortic Valvuloplasty from the PARTNER trial (placement of AoRtic TraNscathetER valve trial). J Am Coll Cardiol Intv. 2015;8:324–33.CrossRef
23.
go back to reference Platt RW, Hutcheon JA, Suissa S. Immortal time bias in epidemiology. Curr Epidemiol Rep. 2019;6:23–7.CrossRef Platt RW, Hutcheon JA, Suissa S. Immortal time bias in epidemiology. Curr Epidemiol Rep. 2019;6:23–7.CrossRef
24.
go back to reference Otto CM, et al. 2017 ACC expert consensus decision pathway for Transcatheter aortic valve replacement in the Management of Adults with aortic stenosis: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2017;69:1313–46.CrossRef Otto CM, et al. 2017 ACC expert consensus decision pathway for Transcatheter aortic valve replacement in the Management of Adults with aortic stenosis: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2017;69:1313–46.CrossRef
Metadata
Title
Restricted mean survival time of older adults with severe aortic stenosis referred for transcatheter aortic valve replacement
Authors
Julia Rodighiero
Nicolo Piazza
Giuseppe Martucci
Marco Spaziano
Kevin Lachapelle
Benoit de Varennes
Marie-Claude Ouimet
Jonathan Afilalo
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01572-4

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue